SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Rhea-AI Summary

Scienture (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) oral suspension, 10 mg/mL was added to formularies of key national payors, expanding availability to over 100 million covered lives in the United States.

Arbli is the first FDA‑approved ready‑to‑use oral suspension of losartan potassium. According to IQVIA (MAT June 2025), the U.S. losartan market is approximately $256 million in annual sales with >71 million prescriptions per year, representing a commercial opportunity. The company said plan design and utilization management may affect individual out‑of‑pocket costs.

Positive

• Formulary coverage expanded to over 100 million covered lives
• First FDA‑approved ready‑to‑use losartan oral suspension
• U.S. losartan market ≈ $256M annual sales (IQVIA, MAT June 2025)
• More than 71 million prescriptions written annually for losartan

Negative

• Access may be limited by plan design and utilization management

Insights

Market Access Strategist

Formulary additions covering >100M lives materially improve commercial reach for Arbli™ and create a clear revenue access pathway.

SCIENTURE added Arbli™ (losartan potassium) Oral Suspension to major national formularies, extending coverage to over 100 million covered lives and targeting a U.S. losartan market cited at $256 million (MAT June 2025) with more than 71 million annual prescriptions. This moves the product from launch-only visibility to broad payer access, which directly affects the addressable patient pool for a ready-to-use oral suspension alternative to tablets.

The commercial upside depends on three explicit items in the release: plan placement depth, patient cost-sharing under each plan, and any utilization management rules mentioned as possible. The statement that plans will provide “more affordable access” is conditional on plan design; this phrasing does not quantify formulary tier, prior authorization, or step therapy requirements. Watch actual coverage tiers and utilization edits as they determine real capture rates.

Near-term milestones to monitor include reported prescription volumes and net sales in upcoming company updates, any disclosed formulary tier or prior authorization language, and early patient access metrics over the next 12 months. If uptake data show meaningful conversion from existing tablet prescriptions, the formulary additions could translate into measurable revenue growth; absent those metrics, the news primarily signals improved market access rather than proven commercial performance.

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide

COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli^™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. This inclusion extends availability to over 100 million covered lives across the United States.

Arbli^™ is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. According to IQVIA data (MAT June 2025), the U.S. losartan market totals approximately $256 million in annual sales, with more than 71 million prescriptions written each year, presenting a significant commercial opportunity for Scienture. This is an important milestone that provides patients with options for affordable access to treatment.

“The addition of Arbli™ to major national formularies underscores the confidence health plans have in our products and represents a tangible win for patients who deserve effective and affordable treatment options,” commented Narasimhan Mani, President and co-CEO of Scienture. “Patients covered under these plans will now have more affordable access to Arbli™, with lower out-of-pocket costs depending on plan design and utilization management.”

“Expanding formulary access for Arbli^™ demonstrates our commitment to driving sustainable growth while improving public health outcomes,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We see this as just the beginning of a broader effort to make Scienture’s portfolio available to millions more across the country.”

About Arbli^™

Arbli^™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli^™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli^™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli^™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli^™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli^™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
  
  

IMPORTANT SAFETY INFORMATION

• Do not take Arbli^™ when pregnant. When pregnancy is detected, discontinue Arbli^™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli^™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
  
• Do not co-administer Arbli^™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli^™ in patients with renal impairment (GFR <60 mL/min).
  
• Do not administer Arbli^™ in patients with severe hepatic impairment. Arbli^™ has not been studied in patients with severe hepatic impairment.
  
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
  
  

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com

FAQ

What did Scienture announce about Arbli (SCNX) on November 4, 2025?

Scienture said Arbli oral suspension was added to major national formularies, expanding access to over 100 million covered lives.

How many covered lives does Arbli formulary inclusion reach for SCNX?

The company reported formulary coverage reaching over 100 million covered lives across the U.S.

What makes Arbli commercially notable for SCNX investors?

Arbli is the first FDA‑approved ready‑to‑use losartan suspension in a U.S. losartan market of ≈ $256M annual sales.

How large is the U.S. losartan market cited in the SCNX announcement?

IQVIA data (MAT June 2025) shows about $256 million in annual sales and >71 million prescriptions per year.

Will formulary coverage guarantee low out‑of‑pocket costs for SCNX patients?

Not necessarily; the company said out‑of‑pocket costs depend on plan design and utilization management.

Does the SCNX announcement state any sales or revenue guidance tied to Arbli?

No— the announcement cites market size and formulary access but does not provide company sales or revenue guidance.